Loading…
Operates in Healthcare Services — General medicine - private practice. Per the activity note to the FY2024 annual report, the company provides obstetric and gynecological services. Founded in 2012; renamed to Miamed Consilium in April 2024; provides maternity care and gynecological services.
| Ratio | 2022 | 2023 | 2024 |
|---|---|---|---|
| Margins | |||
| Gross Margin | 100.0% | 97.3% | 97.8% |
| EBITDA Margin | -20.6% | 173.0% | -5.1% |
| EBITDAR | -97 | 588 | -18 |
| EBITDAR Margin | -20.6% | 173.0% | -5.1% |
| EBIT Margin | -32.0% | 112.0% | -29.0% |
| Net Profit Margin | -32.7% | 172.6% | -29.1% |
| Operating Expense % of Sales | 120.6% | 75.7% | 102.9% |
| Returns | |||
| Return on Assets (ROA) | -11.8% | 38.2% | -11.6% |
| Return on Equity (ROE) | -72.7% | 57.1% | -12.8% |
| ROIC [EBIT / Invested Capital] | -17.2% | 36.3% | -13.0% |
| Leverage & debt balances | |||
| Debt-to-Assets | 70.4% | 27.1% | 0.0% |
| Debt-to-Equity | 4.32x | 0.41x | 0.00x |
| Debt-to-EBITDA | N/A | 0.71x | N/A |
| Equity-to-Assets | 16.3% | 66.9% | 90.5% |
| Net Debt | 663 | 20 | -18 |
| Cash & Equivalents | 253 | 396 | 18 |
| Total Debt | 916 | 417 | N/A |
| Liquidity & working capital | |||
| Current Ratio | 1.19x | 3.02x | 10.54x |
| Quick Ratio | 1.19x | 3.02x | 10.54x |
| Cash Ratio | 0.23x | 0.78x | 0.22x |
| Total Current Assets | 1,302 | 1,535 | 875 |
| Total Current Liabilities | 1,090 | 508 | 83 |
| Inventory | N/A | N/A | N/A |
| Trade Receivables | 23 | 219 | 21 |
| Trade Payables | 134 | 5 | 5 |
| Net Working Capital | 212 | 1,027 | 792 |
| Net Working Capital % of Revenue | 45.0% | 302.1% | 227.5% |
| Trade Working Capital | -111 | 214 | 17 |
| Trade Working Capital % of Revenue | -23.6% | 62.9% | 4.8% |
| Change in Trade Working Capital | N/A | 325 | -197 |
| Turnover & efficiency | |||
| Inventory Turnover | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A |
| Receivables Turnover | 20.91x | 1.55x | 16.52x |
| Days Sales Outstanding (DSO) | 17.5 | 235.3 | 22.1 |
| Payables Turnover | N/A | 1.69x | 1.68x |
| Days Payable Outstanding (DPO) | N/A | 216.5 | 216.6 |
| Cash Conversion Cycle | 17.5 days | 18.8 days | -194.5 days |
| Asset Turnover | 0.36x | 0.22x | 0.40x |
| Cash flow & dividends | |||
| Operating Cash Flow | 244 | 144 | -378 |
| Free Cash Flow (OCF − Capex proxy) | 244 | 144 | -378 |
| Cash Conversion (OCF / EBITDA) | N/A | 24.4% | N/A |
| Dividends Declared | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →